Literature DB >> 20464518

Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell cancers.

Hiroshi Hoshikawa1, Yoshihiro Nishiyama, Takehito Kishino, Yuka Yamamoto, Reiji Haba, Nozomu Mori.   

Abstract

PURPOSE: We compared 3'[F-18]fluoro-3'-deoxythymidine (FLT) positron emission tomography (PET) and 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) for PET visualization of head and neck squamous cell cancers (HNSCCs) and evaluated which might better reflect proliferative activity as indicated by the Ki-67 index. PROCEDURES: A total of 43 patients with HNSCCs were examined with FLT-PET and FDG-PET. The PET images were evaluated qualitatively for regions of focally increased metabolism and for semiquantitative analysis the maximum standardized uptake value (SUV) was calculated.
RESULTS: For depiction of primary tumours, the sensitivity of both approaches was 100%. The mean (± SD) SUV for FLT (5.65 ± 2.96) was significantly lower than that for FDG (10.9 ± 4.91; p < 0.0001). No significant differences were found for the T category. However, the mean (± SD) FLT SUV was significantly higher in poorly than in well-differentiated tumours (6.49 ± 3.13 vs. 4.2 ± 2.08; p < 0.04). Similarly, FDG SUVs in poorly and moderately differentiated tumours (12.72 ± 4.8 and 11.46 ± 4.64) were significantly higher than in well-differentiated tumours (7.45 ± 3.51; p < 0.004 and p < 0.02). No significant correlation was observed with the Ki-67 index for either.
CONCLUSION: FLT-PET showed as high a sensitivity as FDG-PET for the detection of primary HNSCC lesions, although uptake of FLT was significantly lower than that of FDG.

Entities:  

Mesh:

Year:  2011        PMID: 20464518     DOI: 10.1007/s11307-010-0331-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  24 in total

1.  Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.

Authors:  Betty S Pio; Cecilia K Park; Richard Pietras; Wei-Ann Hsueh; Nagichettiar Satyamurthy; Mark D Pegram; Johannes Czernin; Michael E Phelps; Daniel H S Silverman
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

2.  Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.

Authors:  H Minn; M Lapela; P J Klemi; R Grénman; S Leskinen; P Lindholm; J Bergman; E Eronen; M Haaparanta; H Joensuu
Journal:  J Nucl Med       Date:  1997-12       Impact factor: 10.057

Review 3.  The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer.

Authors:  Bianca M Klabbers; Adriaan A Lammertsma; Ben J Slotman
Journal:  Mol Imaging Biol       Date:  2003 Jul-Aug       Impact factor: 3.488

4.  Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?

Authors:  A C Buck; H H Schirrmeister; C A Guhlmann; C G Diederichs; C Shen; I Buchmann; J Kotzerke; D Birk; T Mattfeldt; S N Reske
Journal:  J Nucl Med       Date:  2001-05       Impact factor: 10.057

5.  The diagnostic value of positron emission tomography (PET) with radiolabelled fluorodeoxyglucose (18F-FDG) in head and neck cancer.

Authors:  N J Slevin; C D Collins; D L Hastings; M L Waller; R J Johnson; R A Cowan; A R Birzgalis; W T Farrington; R Swindell
Journal:  J Laryngol Otol       Date:  1999-06       Impact factor: 1.469

Review 6.  From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.

Authors:  K Kubota
Journal:  Ann Nucl Med       Date:  2001-12       Impact factor: 2.668

7.  In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography.

Authors:  D L Francis; A Freeman; D Visvikis; D C Costa; S K Luthra; M Novelli; I Taylor; P J Ell
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

8.  18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.

Authors:  David C P Cobben; Bernard F A M van der Laan; Bram Maas; Willem Vaalburg; Albert J H Suurmeijer; Harald J Hoekstra; Pieter L Jager; Philip H Elsinga
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

Review 9.  Clinical applications of PET in oncology.

Authors:  Eric M Rohren; Timothy G Turkington; R Edward Coleman
Journal:  Radiology       Date:  2004-03-24       Impact factor: 11.105

10.  Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas.

Authors:  C Laubenbacher; D Saumweber; C Wagner-Manslau; R J Kau; M Herz; N Avril; S Ziegler; C Kruschke; W Arnold; M Schwaiger
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

View more
  13 in total

1.  Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Yoriko Kajiya; Megumi Jinguji; Nobuaki Nishimata; Shunji Shimaoka; Tohru Nihara; Kuniaki Aridome; Sadao Tanaka; Yoshihiko Fukukura; Atushi Tani; Chihaya Koriyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

2.  Correlations of (18)F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Yoriko Kajiya; Yuko Goto; Megumi Jinguji; Sadao Tanaka; Yoshihiko Fukukura; Atsushi Tani; Michiyo Higashi
Journal:  Eur Radiol       Date:  2014-08-13       Impact factor: 5.315

3.  FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Yoshihiko Fukukura; Yoriko Kajiya; Atushi Tani; Masayuki Nakajo; Yoshiaki Nakabeppu; Hiroshi Arimura; Yoshihiko Nishio; Fumihiko Nakamura; Takashi Yoshiura
Journal:  Eur Radiol       Date:  2015-04-30       Impact factor: 5.315

4.  Single-scan dual-tracer FLT+FDG PET tumor characterization.

Authors:  Dan J Kadrmas; Thomas C Rust; John M Hoffman
Journal:  Phys Med Biol       Date:  2013-01-08       Impact factor: 3.609

Review 5.  Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma.

Authors:  P Castaldi; L Leccisotti; F Bussu; F Miccichè; V Rufini
Journal:  Acta Otorhinolaryngol Ital       Date:  2013-02       Impact factor: 2.124

6.  ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.

Authors:  Flavio Crippa; Roberto Agresti; Marco Sandri; Gabriella Mariani; Barbara Padovano; Alessandra Alessi; Giulia Bianchi; Emilio Bombardieri; Ilaria Maugeri; Mario Rampa; Maria Luisa Carcangiu; Giovanna Trecate; Claudio Pascali; Anna Bogni; Gabriele Martelli; Filippo de Braud
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

7.  Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx.

Authors:  Matthew J Nyflot; Paul M Harari; Stephen Yip; Scott B Perlman; Robert Jeraj
Journal:  Radiother Oncol       Date:  2012-10-13       Impact factor: 6.280

8.  Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.

Authors:  Lars Stelter; Simon Fuchs; Achim A Jungbluth; Gerd Ritter; Valerie A Longo; Pat Zanzonico; Nathanael Raschzok; Igor M Sauer; John S Bomalaski; Steven M Larson
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

9.  Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis.

Authors:  Sheng-Ming Deng; Wei Zhang; Bin Zhang; Yin-Yin Chen; Ji-Hui Li; Yi-Wei Wu
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

Review 10.  Methodology for quantitative rapid multi-tracer PET tumor characterizations.

Authors:  Dan J Kadrmas; John M Hoffman
Journal:  Theranostics       Date:  2013-10-04       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.